Luxa Biotechnology Awarded $4 Million CIRM Grant to Support Clinical Trial of Adult RPESC-RPE-4W Therapy for Dry Age-related Macular Degeneration
RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells (RPESC) that generate retinal pigmented epithelium (RPE) cell progeny (RPESC-RPE).
- RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells (RPESC) that generate retinal pigmented epithelium (RPE) cell progeny (RPESC-RPE).
- Transplantation of progenitor-stage RPESC-RPE cells obtained after four weeks of differentiation (RPESC-RPE-4W) effectively replace the native RPE cells lost during AMD disease progression.
- "We are honored to have CIRM recognize the potential of our unique technology utilizing precursor-stage RPE cells.
- “RPESC-RPE-4W therapy represents a potential breakthrough in the treatment of dry AMD,” said Dr. Abla Creasey, PhD, Vice President of Therapeutics Development at CIRM.